FutuRx logo

FutuRx

Asia, HaMerkaz, Israel, Ness Ziona

Description

FutuRx is the Israeli biotechnology accelerator.

Investor Profile

FutuRx has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Seed (67%)
  • Series Unknown (33%)

Country Focus

  • Israel (100%)

Industry Focus

  • Biotechnology
  • Life Science
  • Health Care
  • Pharmaceutical
  • Biopharma
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does FutuRx frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 3
Fonds de solidarité FTQ
North America, Quebec, Canada, Montréal
Co-Investments: 1
Johnson & Johnson Innovation – JJDC
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
RB
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 2
Israel Innovation Authority
Asia, Yerushalayim, Israel, Jerusalem
Co-Investments: 1
Johnson & Johnson Robotics and Digital Solutions
North America, New Jersey, United States, New Brunswick
Co-Investments: 2
Bukwang Pharmaceutical Co
Asia, Seoul-t'ukpyolsi, South Korea, Seoul
Co-Investments: 1
Takeda Ventures
North America, California, United States, San Diego
Co-Investments: 3

What are some of recent deals done by FutuRx?

Protekt Therapeutics

Ness Ziona, HaMerkaz, Israel

Protekt Therapeutics is a drug development company aiming to develop inhibitors of PKR for various diseases

BiotechnologyHealth CarePharmaceutical
Series UnknownNov 12, 2019
Amount Raised: $4,100,000
Bsense Bio Therapeutics

Ness Ziona, HaMerkaz, Israel

Bsense Bio Therapeutics develops small molecules for the treatment of sensory hyperexcitability related disorders.

BiotechnologyLife ScienceTherapeutics
SeedOct 1, 2018
Amount Raised: $405,000
Ramino Bio

Ness Ziona, HaMerkaz, Israel

Ramino Bio is a private biotech company that develops an oral drug to treat metabolic diseases.

BiopharmaBiotechnologyLife Science
SeedSep 1, 2018